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Intracranial hemodynamic relationships in
patients with cerebral small vessel disease
Gordon W. Blair, MRCP(UK), Michael J. Thrippleton, PhD, Yulu Shi, PhD, Iona Hamilton, BSc,
Michael Stringer, PhD, Francesca Chappell, PhD, David Alexander Dickie, PhD, Peter Andrews, MD,







To investigate cerebrovascular reactivity (CVR), blood flow, vascular and CSF pulsatility, and
their independent relationship with cerebral small vessel disease (SVD) features in patients
with minor ischemic stroke and MRI evidence of SVD.
Methods
We recruited patients with minor ischemic stroke and assessed CVR using blood oxygen
level–dependent MRI during a hypercapnic challenge, cerebral blood flow (CBF), vascular and
CSF pulsatility using phase-contrast MRI, and structural magnetic resonance brain imaging to
quantify white matter hyperintensities (WMHs) and perivascular spaces (PVSs). We used
multiple regression to identify parameters associated with SVD features, controlling for patient
characteristics.
Results
Fifty-three of 60 patients completed the study with a full data set (age 68.0% ± 8.8 years, 74%
male, 75% hypertensive). After controlling for age, sex, and systolic blood pressure, lower white
matter CVR was associated with higher WMH volume (−0.01%/mm Hg per log10 increase in
WMHvolume, p = 0.02), basal ganglia PVS (−0.01%/mmHg per point increase in the PVS score,
p = 0.02), and higher venous pulsatility (superior sagittal sinus −0.03%/mmHg, p = 0.02, per unit
increase in the pulsatility index) but not with CBF (p = 0.58). Lower foramen magnum CSF
stroke volume was associated with worse white matter CVR (0.04%/mm Hg per mL increase in
stroke volume, p = 0.04) and more severe basal ganglia PVS (p = 0.09).
Conclusions
Lower CVR, higher venous pulsatility, and lower foramenmagnumCSF stroke volume indicate
that dynamic vascular dysfunctions underpin PVS dysfunction and WMH development. Fur-
ther exploration of microvascular dysfunction and CSF dynamics may uncover new mecha-





disease: Moving closer to
hemodynamic function
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Cerebral small vessel disease (SVD) causes multiple major
health problems including lacunar ischemic stroke, vascular
dementia, and intracerebral hemorrhage.1 There is no specific
treatment for SVD.2 An improved understanding of disease
mechanisms is required to identify drug targets.
The role of cerebral blood flow (CBF) in SVD is complex:
although lower CBF is associated with more severe SVD in
cross-sectional studies, most longitudinal studies have not
found lower CBF to precede development or progression of
SVD.3 Dynamic measures of CBF may be more sensitive to
small vessel dysfunction.
Cerebrovascular reactivity (CVR) measures the vasculature’s
ability to increase CBF in response to metabolic demands.4
CVR can be assessed by measuring blood flow changes in
response to a vasoactive stimulus such as breathing carbon
dioxide.5 Transcranial Doppler (TCD) ultrasound is com-
monly used but only measures large cerebral arteries.6,7 MRI
techniques measure CVR in all brain tissues, including the
subcortical areas commonly affected by SVD.8 So far, MRI-
based CVR has been assessed in relatively few small studies in
SVD, but used different CVR challenges,4,9–12 and did not
account for potentially confounding clinically relevant variables
(e.g., age, blood pressure [BP], and sex).4
More pulsatile blood flow (larger difference in blood flow
between systolic and diastolic phases) measured outside the
brain is associated with increasing white matter hyper-
intensities (WMHs)13,14 consistent with the hypothesis that
SVD is associated with increased arterial stiffening. MRI
phase-contrast angiography can assess pulsatility and flow in
the intracranial arteries, venous sinuses, and CSF spaces
(aqueduct and foramen magnum) within 1 examination,
concurrently with CVR. However, there are very few studies
of intracranial pulsatility assessed with MRI in aging or SVD15
and no studies in humans of CVR assessed concurrently with
intracranial vascular pulsatility, CSF flow dynamics, or rest-
ing CBF.
We aimed to assess CVR and imaging features of SVD,
concurrently with total CBF, arterial, venous, and CSF
pulsatility. We studied independent patients with minor is-
chemic stroke stratified by SVD burden as representative of
a high-risk group for the clinical effects of SVD. We hy-
pothesized that more severe SVD features on neuroimaging
would be associated with lower CVR, that lower CVR would
associate with increased vascular pulsatility, and that these
relationships would persist after controlling for patient de-
mographic and vascular risk factors.
Methods
Standard protocol approvals, registrations,
and patient consents
All participants provided written informed consent before
enrollment. The study was approved by the UK Health Re-
search Authority National Research Ethics Service Commit-
tee East Midlands, Nottingham 1 (ref. 14/EM/1126).
Patients
We invited all patients presenting to our regional stroke service
between October 2014 and April 2016 with symptomatic
nondisabling ischemic stroke (modified Rankin Scale score
≤316) and whose treating physician agreed could be
approached about the study to take part in the study. We also
invited such patients who had participated in recent previous
prospective studies.17 All patients had a clinical stroke diagnosis
confirmed by a specialist stroke physician and brain imaging
that either confirmed a relevant recent infarct or, if no recent
infarct was visible, excluded any other cause of the presenting
symptoms.17
We excluded patients who were pregnant, unable to lie flat, had
contraindications to MRI (including claustrophobia), moder-
ate to severe chronic respiratory disease or symptomatic cardiac
failure, personal history or first-degree relative with sub-
arachnoid hemorrhage or intracranial aneurysm, uncontrolled
hypertension, or atrial fibrillation with fast ventricular response.
We performed the study assessments at least 1 month after the
patient’s stroke to prevent hemodynamic changes in the acute
phase of stroke (both stroke related and due to commencing
vasoactive secondary prevention medications) from interfering
with the interpretation of vascular function. We requested
participants not to consume caffeinated drinks on the day of
assessment.
We recorded detailed medical histories including clinical
characteristics of presenting stroke, vascular risk factors,
smoking and alcohol use (with alcohol excess defined as con-
suming more than 21 units per week), concurrent medications,
and investigations performed for the presenting stroke (di-
agnostic brain MRI, carotid ultrasound imaging, hematology,
biochemistry, and ECGs).
Glossary
BP = blood pressure; BOLD = blood oxygen level dependent; CBF = cerebral blood flow; CVR = cerebrovascular reactivity;
EtCO2 = end-tidal CO2; FLAIR = fluid-attenuated inversion recovery; IJV = internal jugular vein; ICA = internal carotid artery;
PVS = perivascular space; PI = pulsatility index; RI = resistivity index; ROI = region of interest; SSS = superior sagittal sinus;
SVD = small vessel disease; StS = straight sinus; TCD = transcranial Doppler; TS = transverse sinus; VA = vertebral artery;
WMH = white matter hyperintensity.
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We classified the clinical stroke syndrome according to the
Oxford Community Stroke Project classification18 (in-
dependently assessed by 2 stroke physicians, F.N.D. and
G.W.B.) and the lesion type seen on imaging (independently
assessed by J.M.W. and Y.S.). Any disagreements were re-
solved by discussion. Where no recent ischemic lesion was
evident, the final stroke type was assigned using the clinical
classification. Where the imaging lesion was discordant with
the clinical stroke type, the imaging type was used as the final
classification, as previously.19 We recorded BP 7 times at
specific points of the study visit that included measurements
before, during, and after MRI.
MRI
We performed brain MRI using a 1.5 Tesla GE research MRI
scanner (Signa HDxt; General Electric, Milwaukee, WI) op-
erating in research mode and an 8-channel phased array head
coil. The total imaging time was circa 75 minutes for each
participant, but patients were allowed to move and have a nat-
ural break between each section of scans to ensure that they
remained comfortable. We acquired 3D T1-weighted, axial T2-
weighted, fluid-attenuated inversion recovery (FLAIR), and
gradient echo sequences. We performed blood oxygen level–
dependent (BOLD) MRI scanning with CO2 challenge at
4 mm isotropic resolution acquiring a whole-brain volume
every 3 seconds.8 We performed phase-contrast MRI to mea-
sure pulsatility in the internal carotid arteries, intracranial ve-
nous sinuses, CSF flow (aqueduct and foramen magnum), and
total CBF, as described in detail.23 Full parameters of all MR
sequences are available from Dryad (table e-1, doi.org/10.
5061/dryad.xpnvx0kb3).
The CVR method used BOLD 2-dimensional echo-planar im-
aging with a CO2 challenge (detailed in Ref. 8). Briefly, during
MRI, patients wore an anesthetic face mask, carefully fitted to
avoid gas leak between mask and face, attached to a bespoke
unidirectional breathing circuit (Intersurgical, Wokingham,
United Kingdom). Monitoring equipment recorded the pulse
rate, oxygen saturation, BP (Millennia 3155A and Magnitude
3150 MRI; Invivo, Best, The Netherlands), and end-tidal CO2
(EtCO2; CD3-A AEI Technologies, Pittsburgh, PA) throughout
the examination. During a 12-minute BOLD MRI scan, patients
breathed medical air and 6% CO2 in air (BOC Special Products;
Guildford, United Kingdom) alternately, delivered as 2 minutes
air, 3 minutes CO2, 2 minutes air, 3 minutes CO2, and finishing
with 2 minutes air. We instructed patients to expect a change in
smell and breathing pattern (deeper, faster, or more forceful
breathing), and then each patient tried the facemask and gases
before entering the scanner room. Patients were instructed to
breathe normally and to press a buzzer to stop the scan if required.
Scanning commencedwhen the patientwas fully positioned in the
scanner bore, indicated that they felt comfortable, and BP and
heart rate readings indicated no sign of anxiety or distress. A
physician monitored the patient during CO2 inhalation.
Arterial and venous flowwaveformsweremeasured as described
previously.20–22 Briefly, we used a 2D cine phase-contrast
sequence with retrospective peripheral pulse gating to acquire
32 velocity images per cardiac cycle. We used the following slice
locations to measure flow in the different structures: a slice
superior to the carotid bifurcation and perpendicular to the
internal carotid artery (ICA) walls to measure flow in the ICA,
vertebral arteries (VAs), and internal jugular veins (IJVs);
a coronal-oblique slice intersecting the superior sagittal sinus
(SSS) approximately 2 cm above the torcular and through the
midpoint of the straight sinus (StS) to measure SSS, StS, and
transverse sinus (TS) flow; a slice perpendicular to the aqueduct
for aqueduct CSF flow; and an axial slice at the craniocervical
junction for foramen magnum CSF flow.
Image processing and analysis
For each analysis, investigators were blinded to participant
demographic and clinical data and other outcome data (e.g.,
investigators rating imaging features were blinded to CVR
data). Structural image analysis of SVD features was per-
formed according to the STRIVE criteria23 under the super-
vision of an expert neuroradiologist (J.M.W.).
We (Y.S. and J.M.W.) scored the following features: WMHs
using the Fazekas scale,24 summing periventricular and deep
WMH scores to give a score from 0 to 6; perivascular spaces
(PVSs), scored separately in the basal ganglia and centrum
semiovale, using a validated, semiquantitative ordinal scale
(range 0–4); lacunes (location and number); andmicrobleeds
(BOMBS scale) presence/absence and total number23; atro-
phy score by reference to a normative age template25; and
total SVD score (0–4) by combining WMHs, lacunes,
microbleeds, and PVS scores, as described previously.26
We coregistered each participant’s structural images. We calcu-
lated WMH volumes using a validated semiquantitative tech-
nique described previously.22 Briefly, we generated WMH
probability maps for each participant using FLAIR and T1W
image data. Hyperintense outliers within the white matter sur-
face were defined as voxels with a z score of ≥1.5 on FLAIR to
create an initial estimate of WMH volume. We produced final
estimates using 3D smoothing to account for partial volume
effects and reduce noise beforemanually removing the index and
any previous stroke lesions. We segmented normal-appearing
tissues (cortical gray matter, subcortical gray matter, white
matter, and cerebellum) and whole-brain volume from each
participant’s T1W data and local population-specific probability
maps.27 We calculated intracranial volumes using a semi-
automatic method based on T2*W images. All tissuemasks were
visually inspected and manually corrected as necessary.
We processed CVR images as described previously.8 We gen-
erated voxel-wise CVR maps by regressing the BOLD signal
against EtCO2 and the BOLD scan number (to account for
signal drift). CVR is expressed as % BOLD signal change/mm
Hg change in EtCO2, based on the EtCO2 regressor in the
model. We made additional adjustment for the delay time be-
tween BOLD signal change and EtCO2 change to minimize the
residual sum of squares individually for each voxel, further
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adjusted by 4 seconds to account for the delay between exha-
lation and detection on the EtCO2 monitor caused by the 8-m-
long EtCO2 sample tubing.
We realigned BOLD images (using SPM 8, fil.ion.ucl.ac.uk/
spm/software/spm8/) before determining the transformation
between BOLD and T2W image spaces (using FSL FLIRT28).
We then manually drew 3 subcortical gray matter (thalamus,
putamen, and caudate head) and 4 subcortical white matter
(frontal, posterior, periventricular, and centrum semiovale)
regions of interest (ROIs) on T1W images before transfer to
the BOLD images. Voxels that were part of large vessels or the
patient’s stroke lesionweremanually excluded.We extracted the
mean signal across the ROIs and fitted the CVR model to that
data. We also averaged all gray and white matter regions to give
a combined deep gray matter and white matter CVR value.
To process the phase-contrast data, we drew manual ROIs
around the right and left ICAs and VAs; the sagittal, straight,
right, and left TSs and IJVs; the aqueduct; and the foramen
magnum subarachnoid space. Background ROIs were placed
close to the ROIs to correct background phase error by sub-
tracting the background velocity (noise) from the ROI velocity.
We calculated sum flow and mean velocity for bilateral struc-
tures, then total CBF as the sum of ICA and VA flow, nor-
malized to total brain volume and expressed as mL/min/100
mL brain tissue. Pulsatility index (PI) in each structure was
calculated as (Flowmaximum − Flowminimum)/Flowmean;
resistivity index (RI) was calculated as (Flowmaximum −
Flowminimum)/Flowmaximum, with higher values indicating
more pulsatile or more resistive blood flow. The re-
producibility of this approach is published.22 CSF flow
defined the net flow in the aqueduct and foramen magnum,
respectively. We calculated this by integrating the cranial
(positive) and caudal (negative) flow values and expressed
the net flow in mL/min. CSF stroke volume reflects the
total volume of CSF flow per cardiac cycle and is calculated
by averaging the absolute cranial and caudal flow across the
cardiac cycles. These methods for CSF data processing
were similar to those reported in a previous study.29
Sample size and statistical analysis
Only limited data existed to calculate sample size, however we
estimated detecting a relative difference in CVR of 25% be-
tween those with low vs high WMH burden based on pe-
ripheral vascular function data. Allowing for a 10% scan failure
rate, we aimed to recruit 60 participants.
We performed statistical analyses once the study data set was
finalized and the database locked for editing, using R version
3.3.0 (cran.r-project.org/) and the additional packages
Hmisc, texreg, data.table, htmlTable, car, and psych. We
assessed distribution of all variables before analysis and log
transformed the WMH volumes and atrophy scores due to
a skewed distribution. The BP values presented are means of
the 7 readings taken across the visit. We assessed the relation
of demographic factors, SVD features, pulsatility, and CBF
parameters to CVR values using univariate (for comparison
with prior studies) and then multiple linear regression,
adjusting for age, systolic BP, and sex, based on those factors
identified in our systematic review as potentially influencing
CVR4 (univariate associations are presented only for com-
pleteness). In addition, we adjusted for WMH volume in
some models to assess whether relationships were in-
dependent of a coassociation because we found previously
that failure to control for WMH was a potential confound in
assessments of CVR in patients with SVD.30 We examined
the normality of residuals (QQ plots and histograms) and
heteroscedasticity (residual vs fitted values) to assess mod-
eling assumptions. We checked variable inflation factors to
assess for collinearity between variables, with a limit of 2
applied.31
Data availability
The full individual patient data anonymized data set, along
with the study protocol, is available to bona fide researchers
via the University of Edinburgh’s Cerebrovascular Diseases
Database. Access request should be submitted to J.M.
Wardlaw along with a description of any planned analyses.
Results
Study population
We recruited 60 patients; 53 participants completed the full
CVR scanning protocol with complete and fully analyzable
data. Three withdrew due to claustrophobia when wearing the
facemask in theMRI scanner, in 1 movement artifact precluded
analysis, 2 failed to show any EtCO2 or BOLD signal change
with CO2 (likely due to a poor fitting mask), and in 1 patient,
the acquisition was stopped after initial structural scanning
showed an incidental asymptomatic subdural hematoma.
The 53 participants had a mean age of 68.0 ± 8.8 years (range
52–88 years); 39 (74%) were male. The median National
Institutes of Health Stroke Scale score at presentation with
stroke was 2 (range 0–5). At the time of CVR scanning, 75%
had hypertension, 66% had hyperlipidemia, 13% had diabetes,
30% were current smokers or had stopped within the past 12
months, and 19% consumed alcohol regularly in excess of rec-
ommended limits (table 1). Participants were scanned at a me-
dian of 92 days poststroke (range 32–1768 days). We did not
see differences in CVR values between those scanned at less
than 100 days compared with those scanned at more than 100
days since stroke. Thirty-six participants (67.9%) had a final
stroke subtype of lacunar, and 14 (26.4%) had discordant
clinical and imaging stroke subtypes.
Imaging features of SVDwere common: 27 patients (51%) had
deep Fazekas score ≥2, and 29 (55%) had periventricular
Fazekas score ≥2, indicating moderate to severe WMH; 17
(32%) had basal ganglia PVS score ≥3, and 28 (53%) had
centrum semiovale PVS score≥3, indicating high PVS visibility;
35 (66%) had lacunes; and 8 patients (15.1%) hadmicrobleeds.
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Table 1 Demographic data of participants by SVD score
SVD score 0–1 (n = 22) SVD score 2–4 (n = 31) All patients (N = 53)
Age at visit 64.05 ± 7.18 70.87 ± 8.76 68.04 ± 8.75
Male 77% (17) 71% (22) 74% (39)
History of TIA 0% (0) 3% (1) 2% (1)
History of stroke before index stroke 14% (3) 13% (4) 13% (7)
Diabetes 14% (3) 13% (4) 13% (7)
Hypertension 64% (14) 84% (26) 75% (40)
Antihypertensive use prestroke 50% (11) 58% (18) 55% (29)
Atrial fibrillation 0% (0) 16% (5) 9% (5)
Hyperlipidemia 64% (14) 68% (21) 66% (35)
Ischemic heart disease 14% (3) 6% (2) 9% (5)
Current or recent smoking history 32% (7) 19% (6) 25% (13)
History of alcohol excess 27% (6) 13% (4) 19% (10)
Alcohol consumption (units per week) 15.91 ± 23.82 9.06 ± 10.63 11.91 ± 17.49
Current antiplatelet use 100% (22) 84% (26) 91% (48)
Current anticoagulant use 0% (0) 16% (5) 9% (5)
Current statin use 91% (20) 90% (28) 91% (48)
Systolic blood pressure 136.58 ± 15.08 145.90 ± 15.56 142.03 ± 15.91
Diastolic blood pressure 78.62 ± 8.10 80.32 ± 8.23 79.61 ± 8.14
Mean arterial pressure 97.94 ± 9.69 102.18 ± 9.19 100.42 ± 9.55
Pulse pressure 57.97 ± 10.76 65.58 ± 13.64 62.42 ± 12.98
Lesion onMRI to explain compatiblewith participant’s stroke symptoms 50% (11) 90.3% (28) 73.6% (39)
Days since index stroke at the time of study scan, median (IQR) 65 (54–1354) 107 (55–1380) 92 (54–1367)
White matter hyperintensity volume (mL), median (IQR) 7.67 (4.51–10.76) 22.50 (9.38–35.30) 11.93 (6.45–27.10)
WMH volume (% of intracranial volume), median (IQR) 0.50 (0.29–0.77) 1.40 (0.75–2.86) 0.81 (0.45–1.66)
Deep Fazekas score (median) 1 2 2
Periventricular Fazekas score (median) 1 2 2
Total Fazekas score (median) 2 4 3
Basal ganglia PVS score (median) 1 2 2
Centrum semiovale PVS score (median) 2 3 3
Presence of lacunes 23% (5) 97% (30) 66% (35)
Deep atrophy score (median) 2 3 3
Superficial atrophy score (median) 3 4 3
Deep gray matter CVR (all ROI combined) 0.155 ± 0.073 0.125 ± 0.051 0.138 ± 0.062
White matter CVR (all ROI combined) 0.067 ± 0.032 0.049 ± 0.023 0.056 ± 0.028
Lacunar subtype 59% (13) 74% (23) 68% (36)
Total arterial blood flow (mL/min/100 mL brain tissue) 60.86 ± 10.51 59.62 ± 8.12 60.14 ± 9.13
Abbreviations: CVR = cerebrovascular reactivity; IQR=Interquartile Range; PVS = perivascular space; ROI = regions of interest; SVD = small vessel disease.
Continuous variables expressed as mean ± SD. Categorical variables expressed as n (%).
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Univariate analysis
CVR and patient characteristics
Higher systolic BP and pulse pressures were associated with
lower CVR in white matter (all p = 0.01) and gray matter (all
p = 0.01; data available from Dryad [table e-2, doi.org/10.5061/
dryad.xpnvx0kb3]). Lower white matter CVR with increasing
age did not reach statistical significance (p = 0.09). We found no
other statistically significant associations with lower CVR.
CVR and SVD features
Numerous SVD features were associated with lower white
matter CVR (figure 1; data available from Dryad [table e-2,
doi.org/10.5061/dryad.xpnvx0kb3]): higher WMH volume,
worse WMH Fazekas scores, more PVSs, presence of lacunes,
deep atrophy, and total SVD score (all p < 0.05). Lower gray
matter CVR was only associated with periventricular WMH
Fazekas score (p = 0.03) and basal ganglia PVS (p = 0.05).
CVR, pulsatility, and CBF
Lower white matter CVRwas associated with higher PI and RI
in the superior sagittal, straight, and TSs (all p < 0.05), but not
with ICA or IJV PI or RI, or with CBF, (figure 2; data available
from Dryad [table e-2, doi.org/10.5061/dryad.xpnvx0kb3]).
We found no univariate associations between CSF pulsatility
or flow measures and CVR.
Covariate-adjusted analyses
CVR and SVD features
After controlling for age, systolic BP, and sex, we found that
lower white matter CVR remained associated with WMH
volume (−0.01%/mmHg change in EtCO2 per log10 increase
in WMH volume, p = 0.02), periventricular WMH Fazekas
score (−0.01%/mm Hg change in EtCO2 per point increase, p
= 0.02), and basal ganglia PVS score (−0.01%/mm Hg change
in EtCO2 per point increase, p = 0.02). The associations be-
tween these SVD features and gray matter CVRwere no longer
significant (table 2). We observed a similar pattern when pulse
pressure was substituted for systolic BP (data not shown).
Deep and total Fazekas scores, centrum semiovale PVS, lacunes,
any brain atrophy, and total SVD score were not associated with
lower CVR in either white or gray matter (table 2).
We tested the independence of the basal ganglia PVS score
association with lower white matter CVR further by adding
WMH volume to the regression model, which resulted in the
association no longer being significant (data available from
Dryad [table e-3, doi.org/10.5061/dryad.xpnvx0kb3]).
CVR, pulsatility, and CBF
After correcting for age, SBP, and sex, lower white matter
CVR remained associated with higher SSS PI (−0.03%/mm
Hg change in EtCO2 per unit increase in the PI p = 0.02), SSS
RI (−0.07%/mmHg change in EtCO2 per unit increase in the
RI, p = 0.03), and IJV PI (−0.01%/mm Hg change in EtCO2
per unit increase in the PI, p = 0.04), table 3.
Lower white matter CVR was also associated with lower CSF
stroke volume at the foramen magnum (−0.04%/mm Hg
change in EtCO2 per mL decrease in CSF stroke volume, p =
0.04). Furthermore, lower CSF stroke volume was associated
with higher basal ganglia PVS score (−0.96 mL per point
increase in the PVS score, 95% confidence interval −2.087 to
0.146, p = 0.09, data available from Dryad [table e-4, doi.org/
10.5061/dryad.xpnvx0kb3]). We observed a similar pattern
when pulse pressure was substituted for systolic BP (data not
shown). There was no association of white or gray matter
CVR with arterial PI or RI or with CBF (table 3).
We further tested the association of SSS and IJV pulsatility
metrics by adding WMH volume into the regression model.
IJV (but not SSS) PI remained associated with lower white
matter CVR (−0.01%/mm Hg change in EtCO2 per unit
increase in the PI, p < 0.05, data available from Dryad [table
e-3, doi.org/10.5061/dryad.xpnvx0kb3]).
Discussion
We measured concurrently several indices of intracranial mi-
crovascular function in patients with features of SVD on neu-
roimaging who presented with minor ischemic stroke. We
demonstrate that lower CVR is associated with higher WMH
burden and higher basal ganglia PVS, independently of age, sex,
and BP. The association was stronger for white matter than for
subcortical gray matter CVR. Furthermore, the association
between lower CVR and WMH was stronger for periven-
tricular than deep WMH, perhaps reflecting more periven-
tricular vulnerability to hemodynamic changes at distal end
arteries, or differing pathogeneses of WMH by brain region,
providing in vivo support in humans for 2 long-standing hy-
potheses. We also demonstrated that lower white matter CVR
was associated with higher intracranial vascular pulsatility, most
clearly seen in the intracranial venous sinuses and IJV, and with
increased PVS visibility.22 Importantly, we also found that
lower CVRwas associated with lower CSF stroke volume at the
foramen magnum, and also that lower CSF stroke volume was
associated with a trend toward more basal ganglia PVS,
showing for the first time in the intact human cranium, a pos-
sible link between dysfunctional brain interstitial fluid drainage
(evidenced by increased PVS visibility) and impaired CSF
pulsation (thought to help flush interstitial fluid through the
glymphatic system).32 The changes we saw in CVR were small
in absolute terms; however, the relative differences in CVR
were often in the range of 20%–50%. The clinical relevance of
this magnitude of CVR impairment requires further studies
using clinical outcomes. We observed no association of lower
CVR in white or gray matter with resting CBF or of resting
CBF with any measures of SVD.
We recruited patients representative of the range of SVD
features present in patients with typical lacunar or minor
cortical ischemic stroke to ensure relevance to patients who
are commonly affected by SVD.33,34 Confirming that vascular
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Figure 1 White matter CVR and WMH volume, WMH Fazekas score, and PVS scores
(A) White matter CVR and WMH volume β = −0.013 (95% CI
−0.020 to −0.005). (B) White matter CVR and periventricular
Fazekas score β = −0.015 (95% CI −0.024 to −0.007). (C) White
matter CVR anddeep Fazekas scoreβ = −0.008 (95%CI −0.017
to 0.001). (D) Whitematter CVR and basal ganglia PVS score β
= −0.012 (95% CI −0.020 to −0.005). (E) White matter CVR and
centrum semiovale PVS score β = −0.009 (95% CI −0.016 to
−0.001). CI = confidence interval; CVR = cerebrovascular re-
activity; PVS = perivascular space; WMH = white matter
hyperintensity.
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function changes in SVD are not confined to 1 stroke type
increases the generalizability of our findings. Stroke type and
SVD imaging features were carefully assessed by experienced
specialists using standardized, validated image processing and
analysis techniques. CVR was measured by a robust and
standardized technique with quantified reliability and re-
producibility.8 We were careful to control the statistical
analyses for key patient characteristics and WMH volume
where appropriate, all guided by a professional statistician.
There are limitations. Although this study is one of the largest
in the literature to assess CVR in SVD4 and the only study so far
in humans to assess CVR, vascular and CSF pulsatility, and
CBF simultaneously, the sample size limits the number of
comparisons and adjustment variables, and any result should be
considered for clinical plausibility. We reported all results for
transparency and to aid interpretation.We recruitedmoremale
than female participants, similar to previousmild stroke cohorts
in our region. There is also an inherent selection bias in studies
using complex imaging techniques and longer scan lengths, as
only participants at the milder end of the disease spectrum and
with less severe comorbidities are agreeable to participation and
can tolerate the procedures. We used a 1.5T MRI scanner;
however, the main impact of this vs a 3T scanner is less crisp
structural resolution of the BOLD MRI image, which may
affect the precision of tissue localization, but not signal mag-
nitude.35 However, because we registered all the images into
a common image processing space and used ROIs obtained
from high-quality structural images mapped onto the CVR
image to extract the tissue-specific CVR signals, the 1.5T MRI
is unlikely to have affected the tissue associations.
We found a strong association of lower CVR withWMH visual
score and volume. However, the Fazekas score allowed us to
detect the novel finding of a stronger association between lower
CVR and periventricular than deep WMH. This could reflect
reduced vascularity of the distal perforating arterioles making
periventricular tissue more vulnerable to developing SVD. This
is consistent with recent findings in 2 similar populations where
Figure 2 Relationship of white matter CVR, foramen magnum CSF stroke volume, and superior sagittal sinus pulsatility
index
(A) White matter CVR and foramen magnum CSF
stroke volume β = 0.033 (95% CI −0.004 to 0.070). (B)
White matter CVR and superior sagittal sinus PI β =
−0.044 (95% CI −0.073 to −0.014). (C) Foramen mag-
numCSF stroke volume and superior sagittal sinus PI
β = −0.249 (95% CI −0.477 to −0.020). CI = confidence
interval; CVR = cerebrovascular reactivity; PI = pul-
satility index.
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direct visualization of vessel morphology in the retina, a vas-
cular bed homologous to the cerebral microvasculature, found
that reduced retinal arteriolar branching complexity was asso-
ciated with WMH and other SVD features.36 The finding of
a stronger association between lower CVR and periventricular
rather than deep WMH should be replicated in future studies,
which should examine regional WMH rather than just total
volume, because we show that total volume may obscure im-
portant differences in relationships between SVD lesions and
microvascular function.
Associations between CVR andWMH in previous studies have
varied. Lower CVR has been found in association with higher
WMH volume in studies of patients with Alzheimer disease37
and older people withWMH38 (total N = 58). Lower CVR has
been associated with higher visual rating measures of WMH in
patients with hereditary cerebral amyloid angiopathy with se-
vere WMH and microbleeds,39 patients with stroke, and
patients older than 50 years with WMH with neurologic
symptoms9–12 (total N = 152). Areas of normal white matter
with lower CVR have also been shown to precede development
of WMH.11
Of the 3 studies (total N = 197) that have shown no association
between CVR and WMH, it is notable that the WMH burden
of the participants was low.40–42 One of these studies also used
a CVR method that is very different to all other studies pub-
lished in the literature.42 In terms of age range of included
participants, WMH burden, presence of clinically evident vas-
cular disease, and CVRmethodology, our study is more similar
to the studies that demonstrated associations of lower CVR
with more WMH.
We did not find associations of CVR with lacunes or micro-
bleeds. This may be due to lack of statistical power but could
also reflect different mechanisms driving development of
different SVD imaging features.
Our systematic review highlighted the variability of CVR
associations with regard to patient characteristics.4 The asso-
ciation of lower CVRwith higher BPwas seen in some previous
studies,40,43 but BP associations with CVR were unclear in
many other studies. A trend for increasing age to be associated
with lower CVR narrowly failed to reach significance in our
study, but age was associated with lower CVR in several other
studies.40,41,44,45 The lack of a definite age-CVR relationship in
the present studymay reflect poorer brain vascular health in the
younger compared with the older patients with stroke because
patients who experience a stroke aged in their 40s or 50s may
have worse vascular health than those who do not experience
stroke until their ninth decade. This paradox has almost cer-
tainly dampened the expected age effect. The studies showing
age effects either studied healthy elderly41,44 or vascular disease
participants over a younger, narrower,40 age range than this
study, missing out the effects of the arguably healthier older
participants.
Lower CVR may be associated with other markers of vascular
health and symptoms. Lower CVR was associated with raised
inflammatorymarkers46 andmore rapid decline in gait speed in
patients with diabetes47 andwith decreased insulin sensitivity in
Table 2 CVR association with stroke subtype and SVD imaging markers
Deep gray matter CVR White matter CVR VIF range
Stroke type (lacunar vs cortical) β = 0.006 (−0.031 to 0.043) p = 0.73 β = 0.001 (−0.015 to 0.264) p = 0.89 1.07–1.16
WMH volume (normalized to ICV) β = −0.021 (−0.043 to 0.000) p = 0.05 β = −0.012 (−0.021 to −0.002) p = 0.02 1.10–1.58
Periventricular Fazekas score β = −0.023 (−0.047 to 0.002) p = 0.07 β = −0.013 (−0.023 to −0.002) p = 0.02 1.12–1.48
Deep Fazekas score β = −0.011 (−0.033 to 0.011) p = 0.30 β = −0.005 (−0.015 to 0.005) p = 0.30 1.10–1.35
Total Fazekas β = −0.009 (−0.021 to 0.003) p = 0.14 β = −0.005 (−0.010 to 0.001) p = 0.08 1.11–1.41
PVS score—basal ganglia β = −0.019 (−0.039 to 0.001) p = 0.07 β = −0.011 (−0.019 to −0.002) p = 0.02 1.10–1.41
PVS score—centrum semiovale β = −0.017 (−0.034 to 0.001) p = 0.06 β = −0.007 (−0.014 to 0.001) p = 0.08 1.11–1.21
Lacunes β = −0.017 (−0.056 to 0.022) p = 0.38 β = −0.010 (−0.028 to 0.007) p = 0.23 1.11–1.29
Deep atrophy β = −0.011 (−0.046 to 0.024) p = 0.53 β = −0.010 (−0.025 to 0.005) p = 0.20 1.10–1.33
Superficial atrophy β = −0.011 (−0.054 to 0.032) p = 0.62 β = −0.006 (−0.024 to 0.013) p = 0.56 1.12–1.36
Combined atrophy β = −0.012 (−0.055 to 0.030) p = 0.56 β = −0.009 (−0.028 to 0.009) p = 0.32 1.10–1.40
Brain parenchymal volume (normalized to ICV) β = 0.38 (−0.175 to 0.936) p = 0.17 β = 0.010 (−0.240 to 0.259) p = 0.94 1.12–1.32
SVD score (high vs low) β = −0.026 (−0.063 to 0.011) p = 0.17 β = −0.011 (−0.028 to 0.005) p = 0.17 1.14–1.57
Abbreviations: CVR = cerebrovascular reactivity; ICV = intracranial volume; PVS = perivascular space; SVD = small vessel disease; VIF = variable inflation factor;
WMH = white matter hyperintensity.
All multivariable regression models adjusted for age, sex, and systolic blood pressure. Standardized β coefficient, 95% confidence interval, and p value.
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obese individuals with insulin resistance.48 These suggest that
inflammation may drive CVR impairment and that more sen-
sitive clinical markers of reduced CVR and SVD should be
evaluated. The literature on CVR and cognitive performance is
inconclusive.49
Higher middle cerebral artery pulsatility has previously been
associated with WMH on TCD.6 We have shown associations
of venous sinus pulsatility with WMH and PVS22 and now
extend that finding to show association of more pulsatile blood
flowwith lowerCVR.Higher pulsatility reflects a stiffer vascular
bed. Histology in SVD reveals arteriolar sclerosis. Much less is
known about venous changes, but collagenosis of the venular
wall is described. In combination, lower CVR and higher pul-
satility reflect a less adaptive and compliant vascular bed. This
potentially results in higher shear forces being generated by
blood flow and often results in a peak blood flowwaveform that
while higher is also shorter and therefore potentially reduces
blood flow over the whole cardiac cycle. The association of
increased PVS with lower CVR, in addition to higher in-
tracranial vascular pulsatility, has not been described pre-
viously.22 Visible PVSs are associated with hypertension,
increasing age, systemic and intracerebral inflammation, other
SVD features likeWMHs andmicrobleeds, and increased risk of
dementia.1 Longitudinal studies are required to demonstrate
whether PVS visibility precedes or follows impairments in CVR
or changes in vascular or CSF pulsatility. PVSs are part of the
brain’s waste clearance and immune defense system, recently
referred to as the glymphatic system50; in this regard, it is in-
teresting that we detected altered pulsation of the CSF at the
foramenmagnum in associationwith lower CVR andwith worse
PVS because in experimental models, reduced PVS flushingmay
lead to failed clearance of metabolic debris and PVS dilation.32,50
Lower CSF stroke volume could indicate reduced CSF flux
around the base of the brainwith reducedCSFmovement linked
to impaired PVS flushing. Caution is required, however, because
the PVS-CSF stroke volume and CVR associations could be
a coassociation with other SVD features, a common problem in
SVD research30 and should be evaluated further.
We did not find an association between WMH and CBF,
consistent with previous data.3 However, we provide more
support for a vascular dysfunction in SVD: CVR is a measure of
dynamic vessel function, with impairment reflecting an inability
to increase blood flow when required. The mechanisms behind
this may encompass impaired endothelial function, reduced
nitric oxide bioavailability, altered vascular smooth muscle
function, inflammatory exudates damaging the vessel wall, and
PVS function.51More longitudinal data with contemporaneous
vascular function measures and careful adjustment for
Table 3 CVR association with CBF, arterial and venous pulsatility, and CSF flow dynamics
Deep gray matter CVR White matter CVR VIF range
Total CBF β = −0.002 (−0.004 to 0.000) p = 0.08 β = 0.000 (−0.001 to 0.001) p = 0.58 1.12–1.24
ICA pulsatility index β = 0.015 (−0.046 to 0.075) p = 0.62 β = 0.003 (−0.023 to 0.030) p = 0.81 1.15–1.24
Vertebral artery pulsatility index β = 0.014 (−0.034 to 0.062) p = 0.56 β = 0.005 (−0.017 to 0.026) p = 0.67 1.10–1.18
Superior sagittal sinus pulsatility index β = −0.040 (−0.117 to 0.037) p = 0.30 β = −0.038 (−0.070 to −0.006) p = 0.02 1.13–1.21
StS pulsatility index β = −0.030 (−0.132 to 0.073) p = 0.56 β = −0.034 (−0.078 to 0.011) p = 0.13 1.14–1.33
TS pulsatility index β = −0.052 (−0.139 to 0.034) p = 0.23 β = −0.034 (−0.071 to 0.004) p = 0.08 1.11–1.26
IJV pulsatility index β = −0.025 (−0.056 to 0.006) p = 0.11 β = −0.014 (−0.027 to −0.001) p = 0.04 1.01–1.13
ICA RI β = 0.027 (−0.240 to 0.294) p = 0.84 β = 0.011 (−0.106 to 0.128) p = 0.85 1.13–1.31
Vertebral artery RI β = 0.054 (−0.163 to 0.271) p = 0.62 β = 0.013 (−0.083 to 0.108) p = 0.79 1.13–1.27
Superior sagittal sinus RI β = −0.074 (−0.219 to 0.071) p = 0.31 β = −0.070 (−0.131 to −0.009) p = 0.03 1.12–1.20
StS RI β = −0.045 (−0.224 to 0.134) p = 0.62 β = −0.055 (−0.132 to 0.022) p = 0.16 1.13–1.31
TS RI β = −0.077 (−0.226 to 0.073) p = 0.31 β = −0.051 (−0.116 to 0.013) p = 0.12 1.11–1.27
IJV RI β = −0.056 (−0.136 to 0.024) p = 0.16 β = −0.032 (−0.067 to 0.003) p = 0.07 1.01–1.13
Aqueduct CSF flow β = −0.005 (−0.029 to 0.020) p = 0.71 β = −0.002 (−0.012 to 0.009) p = 0.78 1.07–1.19
Aqueduct CSF stroke volume β = 0.045 (−0.213 to 0.304) p = 0.73 β = 0.035 (−0.078 to 0.148) p = 0.54 1.13–1.25
Foramen magnum CSF flow β = 0.001 (−0.003 to 0.005) p = 0.72 β = 0.001 (−0.001 to 0.002) p = 0.51 1.00–1.13
Foramen magnum CSF stroke volume β = 0.003 (−0.082 to 0.087) p = 0.95 β = 0.037 (0.002 to 0.072) p = 0.04 1.01–1.14
Abbreviations: BP = blood pressure; CBF = cerebral blood flow; CVR = cerebrovascular reactivity; ICA = internal carotid artery; IJV = internal jugular vein; RI =
resistivity index; StS = straight sinus; TS = transverse sinus; VIF = variable inflation factor.
All multivariable regression models adjusted for age, sex, and systolic BP. Standardized β coefficient, 95% confidence interval, and p value.
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covariates are required to unpick this pathway, but it is notable
that all the associations of demographic and SVD features with
impaired CVR were stronger in the white matter than the gray
matter despite white matter CVR being around one-third the
magnitude of that in gray matter and white matter CBF being
around half of that in gray matter.3,22 The directionality of CVR
changes in gray matter is similar to white matter, however, and
therefore, lack of statistical significance may reflect lack of
power in this sample. Studies of SVD mechanisms and po-
tential interventions should consider using measures of dy-
namic vascular function such as CVR or pulsatility rather than
resting CBF.39,52
We show novel and independent associations between SVD
features and several measures of impaired cerebral hemo-
dynamics, providing new insights into mechanisms that may
underlie SVD development. Further longitudinal studies,
controlling for confounders (e.g., age, BP, and WMH vol-
ume) will define these changes and delineate the pathway of
SVD development, including the novel observation of im-
paired CSF pulsation. Ultimately, enhanced knowledge of
vascular malfunction will help identify therapeutic targets to
halt or even reverse disease progression, with benefits for
both dementia and stroke prevention.
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